Archived article
Please note that tax, investment, pension and ISA rules can change and the information and any views contained in this article may now be inaccurate.
BSF Enterprise PLC - London-based biotech company is the owner of companies including 3D Bio-Tissues, a pioneer of lab-grown tissues, as well as the corneal replacement company Kerato - Says Kerato enters into a heads of terms agreement and research partnership with the University of Montreal in Canada. Kerato will work with the university to further develop an in-situ gelling cornea that offers a novel treatment for corneal damage and full thickness perforations.
Kerato Managing Director Sarah Greenhalgh says: ‘This project with the University of Montreal marks the next step in the growth and development of Kerato’s corneal regenerative therapy technologies. Stromal stem cells significantly contribute to corneal clarity by replenishing damaged or aged keratocytes. We are excited to be working on a transformative treatment for the repair of corneal damage which can reduce costs for healthcare providers and support improved patient outcomes.’
Current stock price: 4.48 pence
12-month change: down 67%
Copyright 2024 Alliance News Ltd. All Rights reserved.